- Research article
- Open Access
- Open Peer Review
The relationship between spasticity in young children (18 months of age) with cerebral palsy and their gross motor function development
© Gorter et al; licensee BioMed Central Ltd. 2009
- Received: 8 January 2009
- Accepted: 4 September 2009
- Published: 4 September 2009
It is thought that spasticity has an influence on the development of functional motor abilities among children with cerebral palsy (CP). The extent to which spasticity is associated with the change in motor abilities in young children with CP has not been established. The objective of this study is to evaluate the relationship of initial spasticity in young children with CP and their gross motor function development over one year.
Fifty children with CP aged 18 months, GMFCS-levels I-V participated in a longitudinal observational study. Change in gross motor functioning (GMFM-66) was measured over one year. The level of spasticity measured at the first assessment was determined with the Modified Tardieu Scale in three muscle groups of the lower extremity (adductor muscles, the hamstrings and the m. gastrocnemius). The Spasticity Total Score per child was calculated with a maximum score of 12 points.
Spearman's Rho Correlation (-0.28) revealed a statistically significant relationship (p < 0.05) of small strength between the Spasticity Total Score and the change score of the GMFM-66.
Our findings indicate that when measured over one year, spasticity is marginally related to gross motor function development in infants with CP. The initial level of spasticity is only one of the many child, environmental and family factors that determines gross motor development of a young child with CP.
- Cerebral Palsy
- Motor Ability
- Spastic Cerebral Palsy
- Modify Ashworth Scale
- Motor Function Measure
Cerebral palsy (CP) describes a group of permanent disorders, effecting the development of movement and posture, causing activity limitation, that are attributed to non-progressive disturbances that occurred in the developing fetal or infant brain . The motor disorders of CP are often accompanied by disturbances in sensation, perception, cognition, communication, and behaviour, as well as epilepsy and secondary musculoskeletal problems .
Motor impairment in CP can be classified into three different subtypes, i.e. spastic, dyskinetic or the ataxic form . The most common movement disorder in CP is spastic paresis, defined as a posture and movement dependent tone regulation disorder . A broad diversity of muscle function impairments can be present in spastic paresis. Clinical symptoms of impaired muscle function can either be related to an impairment of muscle activation, leading to both deficit (or negative) symptoms (e.g. paresis, loss of voluntary selective motor control) and excess (or positive) symptoms (e.g. spasticity), or to a change in biomechanical properties of muscles and connective tissues . The most prominent symptom in spastic paresis is spasticity. According to a generally accepted and quoted definition of spasticity in both adult and paediatric literature, spasticity is defined as 'a motor disorder characterized by a velocity dependent increase in tonic stretch reflexes (muscle tone) with exaggerated tendon jerks, resulting from hyper-excitability of the stretch reflex, as one component of the upper motor neuron syndrome' [5, 6]. Others, e.g. members of the SPASM consortium, have tried to redefine spasticity to encompass the current understanding of pathophysiology and clinical practice . There is a need for evidence that this wider definition is useful and that measures of spasticity are congruent with the definition . In clinical practice, spasticity is assessed as a velocity-dependent increased resistance to passive muscle stretch.
Despite limited knowledge about the relationship between spasticity and motor abilities, many intervention strategies focus on reduction of spasticity, with the assumption that reduction of spasticity will lead to an increase in motor abilities. There is limited evidence however, that reduction of spasticity in children with CP is related to a better development . Therefore, knowledge of the nature and strength of relationships between the initial impairments in movement, posture and (change in) performance in a child with CP is very important to serve as a base for rehabilitation interventions. Recent cross-sectional studies in children with CP have shown a modest, negative relationship between spasticity and daily activities in children with CP aged three years and older [8–10]. Also in one botulinum toxin type A (BoNT-A) intervention study in 35 children (mean age 5 years) it was found that at baseline spasticity was poorly related to the 66-item version of the Gross Motor Function Measure (GMFM-66) for the gastrocnemius muscles (r < 0.35) and moderately related to the GMFM-66 for the hamstrings (r = -0.55). Moreover, change score correlations between spasticity and GMFM-66-score at each of 2 months and 6 months was no more than fair (i.e. maximum r < 0.40) . In conclusion, spasticity - as a primary impairment in CP - is thought to have an influence on the development of the functional motor abilities, but the extent to which spasticity is related with the change in motor abilities in infants with CP has not been established in a study with a longitudinal design.
The aim of this study is to evaluate the relationship between initial spasticity in the lower limbs of young children (under the age of two years) with CP and the development of their gross motor function over one year. Based on the evidence in the literature we hypothesize that first, spasticity early in life has a negative relationship with gross motor development. Second, the strength of the correlation between initial spasticity and gross motor development is modest, accounting for no more than 16% of explained variation in the change score of the 66-item version of the Gross Motor Function Measure (GMFM-66).
The present study is part of the PERRIN CP 0-5 study, which, in turn, is part of a longitudinal research program entitled Pediatric Rehabilitation Research in the Netherlands (PERRIN). In the PERRIN program, the course and determinants of the functional status of children and adolescents with CP are studied http://www.perrin.nl. The focus in PERRIN CP 0-5 is on the development of activities and participation of young children with CP starting at age 18 months. The protocol has been approved by the Ethics Committee of the University Medical Center Utrecht and by other participating rehabilitation centres and hospitals in the Netherlands (see acknowledgements).
Parents were asked by the paediatrician, child neurologist or rehabilitation physician of their child whether they were willing to participate in the PERRIN CP 0-5 study.
Between April 2003 and December 2006, 77 children under two years of age, corrected age if applicable, were eligible for the present study. Written consent was obtained from 63 mothers and fathers (82% response rate). The diagnosis of CP was evaluated and, in the case of uncertainty checked by an independent neurologist. Children who had additional disorders (besides CP) which had an important and persistent influence on the motor abilities (e.g. Spina Bifida, cardiac impairments, severe bronchopulmonal dysplasia) and parents with insufficient knowledge of the Dutch language which could hamper assessments, were excluded from the study. For the current study, complete data on the GMFM and spasticity were available in 50 out of 63 children at 18 months of age participating in the PERRIN
N = 50
Spastic unilateral right
Spastic unilateral left
Gross motor function was assessed at the age of 18 months (t1) and one year later (t2). Initial spasticity was assessed at t1. All assessments were performed according to the study protocol by a team of trained research assistants with a background in physiotherapy, movement sciences or medicine. To monitor the reliability of the GMFM, all of the assessors were tested using a criterion test videotape.
Gross motor function
Gross motor function of all children was assessed using the Gross Motor Function Measure-66 (GMFM-66) . The GMFM-88 is a standard criterion-referenced measure for detecting and monitoring changes in motor functions . The 88 items of the test assess activities in five dimensions. Each item is scored using a 4-point Likert scale (0-3 with 0 representing the lowest performance level and 3 the highest). The GMFM-66 uses 66 of the 88 items and was developed using Rasch analysis to improve the sensitivity and interpretability of the test . For each child the values of the GMFM-88 were analyzed using the Gross Motor Ability Estimator computing scoring program to acquire an interval-level GMFM-66 score ranging from 0 to 100 (maximum score) which represents a child's overall level of gross motor functions [14, 15]. The GMFM-66 is a valid and reliable measure  with responsiveness to change .
To evaluate the development of gross motor function in one year, the interval-level GMFM-66 scores of the first measurement moment (t1) were deducted from the GMFM-66 scores of the second measurement moment (t2). The result of this deduction was called the GMFM-66 Change Score and reflects the change in GMFM-66 score in one year (i.e. the progression or regression of gross motor functioning in one year).
Spasticity of the muscle groups that are most relevant for gross motor function of the lower extremities (adductor muscles, the hamstrings and the m. gastrocnemius) were assessed with the Modified Tardieu Scale (MTS) , which is a modification of the Tardieu scale . The MTS grades spasticity by measuring the joint angle of the ROM at which an increase in muscle tone ('catch') is encountered at a high velocity (< 1 sec) passive stretch (R1). Acceptable inter-rater reliability of the MTS has been reported in two studies in children with CP [11, 19]. In a third study, however, the intra-class correlation coefficient of the MTS in children with spastic CP did not reach the acceptable limit of good reliability .
Classification of spasticity
Level of spasticity
Cut-off points for R1 (in degrees per muscle group)
1 SD (Right:10.0 Left:10.1)
1 SD (Right: 17.7, Left: 18.0)
1 SD (Right 13.4, Left 13.0)
Classification of spasticity applied to the obtained data in this study.
Level of spasticity
Cut-off points for the angle of spasticity (R1) in our group (in degrees per muscle group)
1 SD (Right:10.0 Left:10.1)
1 SD (Right: 17.7, Left: 18.0)
11 - 50 dorsiflexion
10 dorsiflexion - (-5)plantarflexion
1 SD (Right 13.4, Left: 13.0)
≤ (-5) plantarflexion
Finally, the angles of spasticity in degrees (R1) were classified according to these three levels. Adding these levels for all muscle groups (right and left side) resulted in a maximal score of 12 points. The total value of spasticity per child was named Spasticity Total Score.
Statistical analysis of data was carried out using SPSS-16 (SPSS, Chicago, Illinois, USA). The relationship between the Spasticity Total Score and the GMFM-66 Change Score was expressed by Spearman's Rho. The data were analyzed for the total group (n = 50). We refrained from undertaking additional subgroup analysis because of the difficulty to classify the type of motor disorder and its distribution in children with CP under the age of 2 years accurately. For interpreting the values of the strength of the correlation the guidelines of Cohen  were used. A Spearman's Rho of 0.10 to 0.29 counts as a small, a Rho of 0.30 to 0.49 as a medium and a Rho of 0.50 to 1.00 as a large correlation. The Spearman's Rho square indicates how much variation of the GMFM-66 Change Score was explained by the ordinal Spasticity Total Score.
According to the Spasticity Total Score we used, 17 of the 50 children did not have spasticity at their first assessment. One of these 17 children was classified as dominant dyskinetic movement disorder, five as spastic CP with bilateral involvement and 11 as spastic CP with unilateral involvement.
In the group of children with CP included in this study, the data gathered indicates that there is a statistically significant relationship between spasticity at the age 18 months and gross motor development over one year. Only 8% of the variance in change in motor function could be explained by spasticity as primary impairment. As shown in Figure 1, the change in motor score in the absence of spasticity (total spasticity score = 0) could vary between a 24 point increase (a child with unilateral spastic CP, GMFCS level I) to a decrease of almost 4 points (a child with bilateral spastic CP, GMFCS level V), while a child with severe spasticity in all three muscle groups (total spasticity score = 12, GMFCS level III) had an increase of 8 points in GMFM-score in one year. Both of our hypothesis in this study were confirmed. This study reveals that spasticity early in life is a minimal factor in functional change when considered alone and would be probably less when other child, environment and family factors are included.
In general, assessment of spasticity is difficult. Valid and reliable assessment of spasticity in young children is even more a challenge, and the most common spasticity scales should be interpreted with caution [22, 23]. The Ashworth scale (AS), Modified Ashworth Scale (MAS), Tardieu scale and Modified Tardieu Scale are the most reported measures in children with CP. According to the review by Scholtes et al.  the original Tardieu Scale is the only suitable instrument to measure spasticity because it measures a velocity dependent resistance at three specified velocities. This method is very time consuming and would interfere with the feasibility of using this instrument in young children.
A limitation of the current study is that it was not possible to study the inter-rater reliability of the Modified Tardieu Scale as the assessment was part of a larger comprehensive assessment in young children within the PERRIN CP 0-5 study. Moreover, the assessments have been performed by a team of investigators with different backgrounds and levels of experience, which may result in a higher variance in measurements than in the study of Kilgour et al. . When assessing spasticity with the Modified Tardieu Scale, Fosang et al.  found inter-rater differences of approximately 10 degrees for the adductors, 20 degrees for the hamstrings and 10-15 degrees for the gastrocnemius muscle. These reliability findings are similar with our assessors. Furthermore, with the measurement error taken into account by the recoding of the obtained R1 angles for each muscle group to the spasticity score, it was felt that inter-rater measurement errors - if any - were taken into account for this population. For the study our own composite spasticity score based on the MTS was developed. As a consequence, we do not have data on the reliability of the Spasticity Total Score in young children with CP. A few studies have been published in which classification of spasticity with the Modified Ashworth Scale has been given in adult stroke patients [25, 26]. By adjusting the MAS to a 0-5 scale and applying this scale to the affected flexors at the elbow, wrists and fingers a "Composite Spasticity Index' from 0-15 was made. Ibrahim and Hawamdeh  used the same 'Composite Spasticity Index' as created by Francis et al.  in a group of children with CP. The 0-5 scale was applied to the spastic hip adductors and the spastic knee extensors. Despite its frequent use in clinical practice, the validity and the reliability of the MAS as a measure of spasticity, however, is questioned .
The results of this study are in line with other studies on the modest relationship between spasticity (ICF body function level) and capabilities/performance (ICF activities and participation level) in other pediatric populations[8–11] The strengths of this study are the young age of children with CP (starting under two years of age), a valid instrument with acceptable inter-rater reliability for assessing spasticity (MTS) and a valid and reliable instrument for assessing change in gross motor abilities (GMGM-66). All data collected are from a large clinical based sample of young children diagnosed as having CP, who were receiving a range of accepted medical physical therapy and rehabilitation services. It is believed the sample is representative of the population of young children with CP in The Netherlands, with results able to be generalized to populations in the same age group elsewhere receiving similar types of mixed developmental therapies.
The results do not imply that reducing spasticity in a child with CP can not be beneficial in the attainment of gross motor skills or in the prevention of secondary impairments that could negatively influence the level of motor abilities. Spasticity treatment with botulinum toxin in combination with intensive physical therapy has been shown to be effective, not only in reducing spasticity in the short term, but also in promoting improvement in motor abilities as measured with the GMFM in both young and older children . The study looked at the relationship between initial spasticity and gross motor development occurring over one year in young children with CP under two years of age. A recent study indicates that in children with CP the muscle tone in the gastrocnemius muscle increases significantly from 1 to 4 years of age . To look at the role of spasticity and its relationship with the development of gross motor function and contractures in the long-term these children should be followed longitudinally for a longer period of time.
In conclusion, the findings indicate that spasticity is marginally related to the development of gross motor function in one year in children with CP under the age of two. Knowledge about determinants of gross motor performance may be useful to set realistic rehabilitation goals and provide both patients and parents complete and reliable information about the expected effects of spasticity treatment.
JWG is Principal Investigator of the PERRIN CP 0-5 study. MK is co-ordinator of the PERRIN research program.
The authors would like to thank Dr. Vanessa Scholtes and Dr. Eugene Rameckers for their help and advice.
This research has been performed as part of the PERRIN (Pediatric Rehabilitation Research in the Netherlands) research program, which has been supported by the Netherlands Organisation for Health Research and Development (grant number 1435.0011).
This publication has been supported by financial contribution of McMaster Child Health Research Institute, McMaster University, Hamilton, Canada.
Also the authors wish to thank the children and parents who participated in the PERRIN CP 0-5 study. Further, the authors are grateful to the therapists who administered the GMFM and to the rehabilitation centres and university hospitals throughout the Netherlands that participated in the study. These centers include Rehabilitation Centre De Hoogstraat, Utrecht; VU, University Medical Centre, Amsterdam; Academic Medical Centre, Amsterdam; Erasmus Medical Centre, Rotterdam; Rijndam Rehabilitation Centre, Rotterdam; Leiden University Medical Centre, Leiden; Rijnlands Rehabilitation Centre, Leiden; Sophia Rehabilitation Centre, Delft; Rehabilitation Centre De Trappenberg, Huizen; Rehabilitation Centre Het Roessingh, Enschede.
A preliminary report of the findings of this study was made by the lead author at the American Academy of Cerebral Palsy and Developmental Medicine in Atlanta, USA, September 2008.
- Rosenbaum P, Paneth N, Leviton A, Goldstein M, Bax M, Damiano D: A report: The definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl. 2007, 109: 8-14.PubMedGoogle Scholar
- Surveillance of Cerebral Palsy in Europe (SCPE): Surveillance of Cerebral Palsy in Europe: a collaboration of cerebral palsy surveys and registers. Dev Med Child Neurol. 2000, 42: 816-824. 10.1017/S0012162200001511.View ArticleGoogle Scholar
- Hagberg B, Hagberg G, Beckung E, Uvebrant P: Changing panorama of cerebral palsy in sweden. VIII. prevalence and origin in the birth year period 1991-94. Acta Paediatr. 2001, 90: 271-7. 10.1080/080352501300067532.View ArticlePubMedGoogle Scholar
- Becher JG, Harlaar J, Lankhorst GJ, Vogelaar TW: Measurement of impaired muscle function of the gastrocnemius, soleus, and tibialis anterior muscles in spastic hemiplegia: A preliminary study. J Rehabil Res Dev. 1998, 35: 314-26.PubMedGoogle Scholar
- Lance JW: Symposium synopsis. spasticity: Disordered motor control. 1980, Chicago: Year Book Medical PublishersGoogle Scholar
- Malhotra S, Pandyan A, Day C, Jones P, Hermens H: Spasticity, an impairment that is poorly defined and poorly measured. Clin Rehabil. 2009, 23: 651-8. 10.1177/0269215508101747.View ArticlePubMedGoogle Scholar
- Butler C, Darrah J: Effects of neurodevelopmental treatment (NDT) for cerebral palsy: An AACPDM evidence report. Dev Med Child Neurol. 2001, 43: 778-90. 10.1017/S0012162201001414.View ArticlePubMedGoogle Scholar
- Ostensjo S, Carlberg EB, Vollestad NK: Everyday functioning in young children with cerebral palsy: Functional skills, caregiver assistance, and modifications of the environment. Dev Med Child Neurol. 2003, 45: 603-12. 10.1017/S0012162203001105.View ArticlePubMedGoogle Scholar
- Abel MF, Damiano DL, Blanco JS, Conaway M, Miller F, Dabney K: Relationships among musculoskeletal impairments and functional health status in ambulatory cerebral palsy. J Pediatr Orthop. 2003, 23: 535-41. 10.1097/00004694-200307000-00022.PubMedGoogle Scholar
- Ross SA, Engsberg JR: Relationships between spasticity, strength, gait, and the GMFM-66 in persons with spastic diplegia cerebral palsy. Arch Phys Med Rehabil. 2007, 88: 1114-20. 10.1016/j.apmr.2007.06.011.View ArticlePubMedGoogle Scholar
- Wright FV, Rosenbaum PL, Goldsmith CH, Law M, Fehlings DL: How do changes in body functions and structures, activity, and participation relate in children with cerebral palsy?. Dev Med Child Neurol. 2008, 50: 283-9. 10.1111/j.1469-8749.2008.02037.x.View ArticlePubMedGoogle Scholar
- Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B: Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997, 39: 214-23.View ArticlePubMedGoogle Scholar
- Gorter JW, Ketelaar M, Rosenbaum P, Helders PJ, Palisano R: Use of the GMFCS in infants with CP: the need for reclassification at age 2 years or older. Dev Med Child Neurol. 2009, 51: 46-52. 10.1111/j.1469-8749.2008.03117.x.View ArticlePubMedGoogle Scholar
- Russell DJ, Avery LM, Rosenbaum PL, Raina PS, Walter SD, Palisano RJ: Improved scaling of the gross motor function measure for children with cerebral palsy: Evidence of reliability and validity. Phys Ther. 2000, 80: 873-85.PubMedGoogle Scholar
- Russell DJ, Rosenbaum PL, Avery LM, Lane M: Gross motor function measure (GMFM-66 & GMFM-88) User's manual. 2002, Hamilton, Ontario: Mac Keith PressGoogle Scholar
- Vos-Vromans DC, Ketelaar M, Gorter JW: Responsiveness of evaluative measures for children with cerebral palsy: The gross motor function measure and the pediatric evaluation of disability inventory. Disabil Rehabil. 2005, 27: 1245-52. 10.1080/09638280500076178.View ArticlePubMedGoogle Scholar
- Boyd RN, Graham HK: Objective measurement of clinical findings in the use of botulinum toxin type a for the management of children with cerebral palsy. Eur J Neurol. 1999, 6: S23-S35. 10.1111/j.1468-1331.1999.tb00031.x.View ArticleGoogle Scholar
- Held JP, Pierrot-Deseilligny E: Le bilan moteur central. 1969, Paris: JB Bailiere et filsGoogle Scholar
- Fosang AL, Galea MP, McCoy AT, Reddihough DS, Story I: Measures of muscle and joint performance in the lower limb of children with cerebral palsy. Dev Med Child Neurol. 2003, 45: 664-70. 10.1017/S0012162203001245.View ArticlePubMedGoogle Scholar
- Yam WK, Leung MS: Interrater reliability of modified ashworth scale and modified tardieu scale in children with spastic cerebral palsy. J Child Neurol. 2006, 21: 1031-5. 10.1177/7010.2006.00222.View ArticlePubMedGoogle Scholar
- Cohen J: Statistical power analysis for the behavioral sciences. 1988, Hillsdale, N.J.: L. Erlbaum Associates, 2Google Scholar
- Mutlu A, Livanelioglu A, Gunel MK: Reliability of ashworth and modified ashworth scales in children with spastic cerebral palsy. BMC Musculoskelet Disord. 2008, 10 (9): 44-10.1186/1471-2474-9-44.View ArticleGoogle Scholar
- Scholtes VA, Becher JG, Beelen A, Lankhorst GJ: Clinical assessment of spasticity in children with cerebral palsy: A critical review of available instruments. Dev Med Child Neurol. 2006, 48: 64-73. 10.1017/S0012162206000132.View ArticlePubMedGoogle Scholar
- Kilgour G, McNair P, Stott NS: Intrarater reliability of lower limb sagittal range-of-motion measures in children with spastic diplegia. Dev Med Child Neurol. 2003, 45: 391-9. 10.1017/S0012162203000744.View ArticlePubMedGoogle Scholar
- Francis HP, Wade DT, Turner-Stokes L, Kingswell RS, Dott CS, Coxon EA: Does reducing spasticity translate into functional benefit? an exploratory meta-analysis. J Neurol Neurosurg Psychiatry. 2004, 75: 1547-51. 10.1136/jnnp.2003.025551.View ArticlePubMedPubMed CentralGoogle Scholar
- Bohannon RW, Smith MB: Interrater reliability of a modified ashworth scale of muscle spasticity. Phys Ther. 1987, 67: 206-7.PubMedGoogle Scholar
- Ibrahim AI, Hawamdeh ZM: Evaluation of physical growth in cerebral palsied children and its possible relationship with gross motor development. Int J Rehabil Res. 2007, 30: 47-54. 10.1097/MRR.0b013e328013dad8.View ArticlePubMedGoogle Scholar
- Bartlett DJ, Palisano RJ: A Multivariate Model of Determinants of Motor Change for Children With Cerebral Palsy. Phys Ther. 2000, 80 (6): 598-614.PubMedGoogle Scholar
- Scholtes VA, Dallmeijer AJ, Knol DL, Speth LA, Maathuis CG, Jongerius PH: Effect of multilevel botulinum toxin a and comprehensive rehabilitation on gait in cerebral palsy. Pediatr Neurol. 2007, 36: 30-9. 10.1016/j.pediatrneurol.2006.09.010.View ArticlePubMedGoogle Scholar
- Hagglund G, Wagner P: Development of spasticity with age in a total population of children with cerebral palsy. BMC Musculoskelet Disord. 2008, 9: 150-10.1186/1471-2474-9-150.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2474/10/108/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.